See the article here:
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
PDS Biotechnology Announces Details of Virtual KOL Event
Read the original post:
PDS Biotechnology Announces Details of Virtual KOL Event
Ocuphire Pharma to Present at the Aegis Virtual Conference
Read this article:
Ocuphire Pharma to Present at the Aegis Virtual Conference
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
View original post here:
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process
Phase 2 data for ERLEADA® ?(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised…
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk…
Compass Pathways to announce first quarter financial results on May 8, 2024
Declaration of shares and voting rights April 30, 2024 – VALNEVA SE
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa…
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the…
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Chromocell Issues Letter to Stockholders from Chief Executive Officer
See the article here:
Chromocell Issues Letter to Stockholders from Chief Executive Officer